Miglitol
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Miglitol: From Type 2 Diabetes to Type 1 Diabetes
Note: The five highest-scoring predictions (for example focal stiff limb syndrome and classic stiff person syndrome) have no trials or literature and no plausible mechanism. This report therefore covers type 1 diabetes mellitus, the only predicted indication with real supporting evidence.
One-Sentence Summary
Miglitol is an oral alpha-glucosidase inhibitor marketed for type 2 diabetes. The TxGNN model predicts it may be useful as an add-on to insulin in type 1 diabetes mellitus (score 99.60%). Support is 1 completed Phase 3 open trial (no results posted) and about 15 publications, mostly small and dated studies from 1986 to 2011.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes (inferred from the pack’s rationale text, since the US license records list no indication text) |
| Predicted New Indication | Type 1 diabetes mellitus (rank 10 of 10 predictions) |
| TxGNN Prediction Score | 99.60% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 6 (all under ANDA203965) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the record. Miglitol is known to be an intestinal alpha-glucosidase inhibitor. It delays carbohydrate digestion and absorption, which flattens the rise in blood glucose after meals.
Even with intensive insulin therapy, many people with type 1 diabetes have sharp postprandial glucose spikes. Slowing carbohydrate absorption can reduce these spikes and the insulin needed at meals. This is the same mechanism that makes miglitol useful in type 2 diabetes, so the prediction is biologically coherent.
The evidence supports miglitol only as an adjunct to insulin, not as a standalone therapy. Because miglitol is already marketed, its safety profile is known. The other high-scoring predictions (stiff person syndromes, lipodystrophies, opsismodysplasia, pancreatic agenesis, thiamine-responsive dysfunction syndrome) show no plausible mechanism and are likely graph-neighborhood artifacts.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00213109 | Phase 3 | Completed | Not reported | Open (non-randomized) trial of miglitol in insulin-treated type 1 diabetes. It targets the exact drug and indication, but no results are provided. |
Five other trials returned by the search (NCT02475499, NCT02476760, NCT02456428, NCT06449235, NCT03492580) are observational or other-drug studies in type 2 diabetes. NCT01697592, a Phase 3 study of omarigliptin, was also returned, and its population could not be confirmed. None involves miglitol in type 1 diabetes, so none is counted as evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24843410 | 2010 | Clinical study | J Diabetes Investig | Miglitol plus insulin in type 1 diabetes, where postprandial spikes persist despite intensive insulin. |
| 21869539 | 2011 | Clinical study | Endocr J | 11 type 1 patients on intensive insulin took miglitol 25 mg, then 50 mg, three times daily. Outcomes were insulin dose, body weight, hypoglycemia and incretin responses. |
| 2060451 | 1991 | Clinical study | Diabetes Care | Alpha-glucosidase inhibition as an insulin adjunct: effect on meal glucose tolerance and insulin timing. |
| 2180090 | 1990 | Clinical study | S Afr Med J | 11 patients. Miglitol 50 mg significantly lowered post-meal glucose increments at 30 and 60 minutes versus placebo. |
| 2663321 | 1989 | Clinical study | Diabetes Res | Single-blind crossover in 13 patients. Miglitol significantly reduced glucose area under the curve, with no change in fasting glucose. |
| 3653827 | 1987 | Clinical study | Fortschr Med | Miglitol in insulin-dependent diabetes, reported as giving improved metabolic control and good tolerance. |
| 8261749 | 1993 | Review | Diabet Med | Review of alpha-glucosidase inhibition as an adjunct in type 1 diabetes. |
| 12073790 | 2002 | Review | Rev Med Liege | Pharmacological approaches to postprandial hyperglycemia, including acarbose and miglitol. |
Several 1986–1988 studies (for example PMIDs 3520133, 3130257 and 3311550) tested earlier alpha-glucosidase inhibitors (Bay compounds) in insulin-dependent diabetes, and they are consistent with this direction. A 2020 case report (PMID 33268615) describes SGLT2 inhibitors added to patients already on miglitol and does not test miglitol itself.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA203965 | Miglitol | Tablet, coated (oral) | Westminster Pharmaceuticals, LLC |
| ANDA203965 | Miglitol | Tablet, coated (oral) | Proficient Rx LP |
The pack lists six licenses in total but returns five records. All five are under ANDA203965 from these two labelers, so the table shows each labeler once.
Safety Considerations
Please refer to the package insert for safety information.
One point from the pack’s assessment applies to type 1 diabetes specifically. Hypoglycemia in patients taking an alpha-glucosidase inhibitor should be treated with oral glucose rather than sucrose, because sucrose absorption is delayed.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism fits, and many small studies show that miglitol lowers postprandial glucose and insulin needs in insulin-treated type 1 diabetes. However, the evidence is old and small-scale, and the only Phase 3 trial is an open-label study with no posted results. It is best treated as a research question for adjunctive use, not a ready-to-adopt indication.
To proceed, the following is needed:
- Results or publication from NCT00213109, or a modern randomized, controlled trial in type 1 diabetes, ideally with continuous glucose monitoring outcomes
- Package insert warnings and contraindications, which are needed before any safety screening
- Formal mechanism of action data
- A hypoglycemia management plan for type 1 patients, including use of oral glucose rather than sucrose
This report is for research reference only and is not medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.